Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30329260 | 0.86 | GRIN2B (0.45) | GRIN2B | |
| SCHEMBL22772849 | 0.82 | GRIN2B (0.61) | GRIN2B | |
| SCHEMBL24783517 | 0.80 | GRIN2B (0.46) | GRIN2B | |
| SCHEMBL23055344 | 0.79 | KDM4E (0.43) | GRIN2B | |
| SCHEMBL25227443 | 0.79 | KMO (0.51) | KMOGRIN2B | |
| SCHEMBL25205678 | 0.79 | KMO (0.51) | KMOGRIN2B | |
| SCHEMBL25227445 | 0.79 | KMO (0.51) | KMOGRIN2B | |
| SCHEMBL25098948 | 0.77 | ALDH1A1 (0.39) | GRIN2B | |
| SCHEMBL29489066 | 0.77 | ALDH1A1 (0.39) | GRIN2B | |
| SCHEMBL23639069 | 0.76 | KMO (0.57) | KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| EP-4104861-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2022-12-21 | — | — | EP | disclosed |
| WO-2021141041-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | 大日本住友製薬株式会社 | 2021-07-15 | — | — | WO | disclosed |
| WO-2021039961-A1 | RING-FUSED PYRAZOLE DERIVATIVE | 大日本住友製薬株式会社 | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | KMO 4398/4885GRIN2B 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.